前收市價 | 112.16 |
開市 | 112.16 |
買盤 | 115.00 |
賣出價 | 119.00 |
拍板 | 200.00 |
到期日 | 2026-01-16 |
今日波幅 | 112.16 - 112.16 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 45 |
Dow Jones biotech leader Amgen, along with streaming giant Netflix and Spotify, are in or near buy zones in today's stock market.
There's probably a big enough pie here for everyone to get a slice.
Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc’s (NASDAQ:AZN) Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-medi